
The Hope Cup golf tournament, to be held May 27, benefits the Melanoma and Skin Cancer Endowment at the Mitchell Cancer Institute.
The latest edition of USA Health magazine, featuring patient stories and news from all facets of the academic health system, is online.
Stay up to date on the latest news from our providers, facilities and researchers at USA Health.
The Hope Cup golf tournament, to be held May 27, benefits the Melanoma and Skin Cancer Endowment at the Mitchell Cancer Institute.
USA Health is now offering the Pfizer-BioNTech vaccine to those who seek care in the emergency department at University Hospital and those who are hospitalized there.
USA Health marked a milestone today on the Alabama Gulf Coast, giving its 50,000th dose of the COVID-19 vaccine.
Hundreds of area residents received the Pfizer-BioNTech vaccine from USA Health at the community-based clinic held in partnership with the City of Mobile and area leaders.
Thousands of educators and school support staff signed up for appointments to receive the Pfizer BioNTech vaccine at the one-day clinic. See the gallery of photos.
While most cases of cancer occur by chance, it’s estimated that 5 to 10 percent of cases can be linked to an inherited genetic variant that can be passed down from generation to generation.
USA Health will host a mass vaccination event at the Mobile Civic Center from 8 a.m. to 6 p.m. on Saturday, Feb. 13, focusing on educators. All vaccine recipients will be required to have appointments.
USA Health Mitchell Cancer Institute is urging women in Alabama to continue their regular screenings for cervical cancer.
USA Health research demonstrating that a vaccine made from patients’ own tumors could extend the lives of women with late-stage ovarian cancer, particularly those without a BRCA gene mutation, has been published in the December 2020 issue of The Lancet Oncology.
Employees at USA Health have begun to receive the newly approved Pfizer COVID-19 vaccine just hours after shipments arrived in Mobile.
Nathaniel Jones, M.D., intends to use findings about DNA damage to see whether there is a correlation between damage and survival rates in endometrial cancer patients. He also wants to determine whether patients with significant DNA damage are more responsive to immunotherapy.
Gary Piazza, Ph.D., professor of pharmacology at the USA College of Medicine and co-lead investigator, discovered and developed a novel RAS inhibitor class.